A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

NCT04150029 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
90
Enrollment
INDUSTRY
Sponsor class

Stopped Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals